Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03886597
Other study ID # IIBSP-OLI-2016-23
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date March 25, 2019
Est. completion date June 15, 2019

Study information

Verified date August 2019
Source Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Olives and olive oil are typical components of the Mediterranean diet being part of its cultural and gastronomic heritage. Since ancient times, olives have been used either for both, oil extraction or whole fruit consumption as table olives. Olive oil stands out from both the nutritional and the health point of view. However, the effect of table olives consumption remains almost unknown. The beneficial properties of olive oil have been initially ascribed to the high concentration of oleic acid. Nowadays, these positive effects have been attributed also to minor compounds such as polyphenols or pentacyclic triterpenes. Table olives contain a higher amount of both polyphenols and pentacyclic triterpenes than their oil, with the same healthy fatty acid profile. Therefore, the present intervention aims at investigating the pharmacokinetic of polyphenols and pentacyclic triterpenes after a single olive intake as well as the assessment of the effect of the consumption of olives during 30 days on the overall health status playing particular attention to the anti-inflammatory, antioxidant and cardiovascular biomarkers.


Recruitment information / eligibility

Status Completed
Enrollment 58
Est. completion date June 15, 2019
Est. primary completion date May 25, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Body Mass Index between 19 and 30 kg/m2.

- Healthy on the basis of physical examination and routine biochemical and hematological laboratory determinations.

- Free acceptance to participate in the study by obtains signed informed consent.

Exclusion Criteria:

- Smoking.

- Alcohol or drug abuse.

- Heavy consumer of stimulating beverages (>5 coffees, teas, chocolate or cola drinks per day) and grapefruit juice.

- Background of allergy, idiosyncrasy or hypersensitivity to drugs.

- Intake of any medication within 2 weeks prior taking the study intervention (except for use of paracetamol in short-term symptomatic treatments), including over-the-counter products (including natural food supplements, vitamins and medicinal plants products), or any enzymatic inductor or inhibitor within 3 months before the drug administration.

- Positive serology for hepatitis B, C or HIV.

- Background or clinical evidence of cardiovascular, respiratory, renal, hepatic, endocrine, gastrointestinal, hematological or neurological disease or other chronic diseases.

- Having undergone major surgery during the previous 6 months.

- Pregnancy or lactation status (if applied).

- Participation in another clinical trial during the 3 months preceding the drug administration.

- Donation of blood during the 4 weeks preceding the drug administration.

- Acute illness four weeks before drug administration.

Study Design


Intervention

Other:
Table Olives
At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 60 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 5 minutes to ingest 60 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.
Table Olives
At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 120 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 10 minutes to ingest 120 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.
Table Olives
All the subjects will perform two experimental sessions of 30 days with 15 days of washout periods within experimental periods. In one experimental session subjects will ingest table olives and in the other session they will act as their own controls following their normal dietary habits. During all the experiment participants will avoid the consumption of products rich in phenolic and triterpenic compounds. Subjects will include the dose of 60 table olives within their normal dietary habits. Consequently, the olives will be consumed two times daily within each main meal; 30 olives before lunch and 30 olives before dinner. Blood samples will be collected at baseline and 15 and 30 days of each experimental session. Tolerability variables and blood pressure will also be measured.

Locations

Country Name City State
Spain Institut de Recerca Hospital de la Santa Creu i Sant Pau - CIM Sant Pau Barcelona

Sponsors (3)

Lead Sponsor Collaborator
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Ministerio de Economía y Competitividad (Spain) AGL 2013-41188R, University of Barcelona

Country where clinical trial is conducted

Spain, 

References & Publications (20)

Bachhav SS, Bhutada MS, Patil SP, Sharma KS, Patil SD. Oleanolic Acid Prevents Increase in Blood Pressure and Nephrotoxicity in Nitric Oxide Dependent Type of Hypertension in Rats. Pharmacognosy Res. 2014 Oct-Dec;7(4):385-92. doi: 10.4103/0974-8490.159575. — View Citation

Cicerale S, Conlan XA, Sinclair AJ, Keast RS. Chemistry and health of olive oil phenolics. Crit Rev Food Sci Nutr. 2009 Mar;49(3):218-36. doi: 10.1080/10408390701856223. Review. — View Citation

Covas MI, Nyyssönen K, Poulsen HE, Kaikkonen J, Zunft HJ, Kiesewetter H, Gaddi A, de la Torre R, Mursu J, Bäumler H, Nascetti S, Salonen JT, Fitó M, Virtanen J, Marrugat J; EUROLIVE Study Group. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med. 2006 Sep 5;145(5):333-41. — View Citation

de la Torre-Carbot K, Chávez-Servín JL, Jaúregui O, Castellote AI, Lamuela-Raventós RM, Fitó M, Covas MI, Muñoz-Aguayo D, López-Sabater MC. Presence of virgin olive oil phenolic metabolites in human low density lipoprotein fraction: determination by high-performance liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Chim Acta. 2007 Feb 5;583(2):402-10. Epub 2006 Nov 2. — View Citation

Dzubak P, Hajduch M, Vydra D, Hustova A, Kvasnica M, Biedermann D, Markova L, Urban M, Sarek J. Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat Prod Rep. 2006 Jun;23(3):394-411. Epub 2006 May 3. Review. — View Citation

Ghanbari R, Anwar F, Alkharfy KM, Gilani AH, Saari N. Valuable nutrients and functional bioactives in different parts of olive (Olea europaea L.)-a review. Int J Mol Sci. 2012;13(3):3291-340. doi: 10.3390/ijms13033291. Epub 2012 Mar 12. Review. — View Citation

Juan ME, Planas JM, Ruiz-Gutierrez V, Daniel H, Wenzel U. Antiproliferative and apoptosis-inducing effects of maslinic and oleanolic acids, two pentacyclic triterpenes from olives, on HT-29 colon cancer cells. Br J Nutr. 2008 Jul;100(1):36-43. doi: 10.1017/S0007114508882979. Epub 2008 Feb 26. — View Citation

Kountouri AM, Mylona A, Kaliora AC, Andrikopoulos NK. Bioavailability of the phenolic compounds of the fruits (drupes) of Olea europaea (olives): impact on plasma antioxidant status in humans. Phytomedicine. 2007 Oct;14(10):659-67. Epub 2007 Sep 17. — View Citation

Liu J, Sun H, Duan W, Mu D, Zhang L. Maslinic acid reduces blood glucose in KK-Ay mice. Biol Pharm Bull. 2007 Nov;30(11):2075-8. — View Citation

Lou-Bonafonte JM, Arnal C, Navarro MA, Osada J. Efficacy of bioactive compounds from extra virgin olive oil to modulate atherosclerosis development. Mol Nutr Food Res. 2012 Jul;56(7):1043-57. doi: 10.1002/mnfr.201100668. Review. — View Citation

Lozano-Mena G, Sánchez-González M, Juan ME, Planas JM. Maslinic acid, a natural phytoalexin-type triterpene from olives--a promising nutraceutical? Molecules. 2014 Aug 4;19(8):11538-59. doi: 10.3390/molecules190811538. Review. — View Citation

Madlala HP, Van Heerden FR, Mubagwa K, Musabayane CT. Changes in Renal Function and Oxidative Status Associated with the Hypotensive Effects of Oleanolic Acid and Related Synthetic Derivatives in Experimental Animals. PLoS One. 2015 Jun 5;10(6):e0128192. doi: 10.1371/journal.pone.0128192. eCollection 2015. — View Citation

Marrugat J, Covas MI, Fitó M, Schröder H, Miró-Casas E, Gimeno E, López-Sabater MC, de la Torre R, Farré M; SOLOS Investigators. Effects of differing phenolic content in dietary olive oils on lipids and LDL oxidation--a randomized controlled trial. Eur J Nutr. 2004 Jun;43(3):140-7. Epub 2004 Jan 6. — View Citation

Martín-Peláez S, Covas MI, Fitó M, KuĊĦar A, Pravst I. Health effects of olive oil polyphenols: recent advances and possibilities for the use of health claims. Mol Nutr Food Res. 2013 May;57(5):760-71. doi: 10.1002/mnfr.201200421. Epub 2013 Mar 1. Review. — View Citation

Melliou E, Zweigenbaum JA, Mitchell AE. Ultrahigh-pressure liquid chromatography triple-quadrupole tandem mass spectrometry quantitation of polyphenols and secoiridoids in california-style black ripe olives and dry salt-cured olives. J Agric Food Chem. 2015 Mar 11;63(9):2400-5. doi: 10.1021/jf506367e. Epub 2015 Feb 26. — View Citation

Poudyal H, Campbell F, Brown L. Olive leaf extract attenuates cardiac, hepatic, and metabolic changes in high carbohydrate-, high fat-fed rats. J Nutr. 2010 May;140(5):946-53. doi: 10.3945/jn.109.117812. Epub 2010 Mar 24. — View Citation

Rodriguez-Rodriguez R, Perona JS, Herrera MD, Ruiz-Gutierrez V. Triterpenic compounds from "orujo" olive oil elicit vasorelaxation in aorta from spontaneously hypertensive rats. J Agric Food Chem. 2006 Mar 22;54(6):2096-102. — View Citation

Sánchez-Quesada C, López-Biedma A, Warleta F, Campos M, Beltrán G, Gaforio JJ. Bioactive properties of the main triterpenes found in olives, virgin olive oil, and leaves of Olea europaea. J Agric Food Chem. 2013 Dec 18;61(50):12173-82. doi: 10.1021/jf403154e. Epub 2013 Nov 22. Review. — View Citation

Uylaser V, Yildiz G. The historical development and nutritional importance of olive and olive oil constituted an important part of the Mediterranean diet. Crit Rev Food Sci Nutr. 2014;54(8):1092-101. doi: 10.1080/10408398.2011.626874. — View Citation

Weinbrenner T, Fitó M, de la Torre R, Saez GT, Rijken P, Tormos C, Coolen S, Albaladejo MF, Abanades S, Schroder H, Marrugat J, Covas MI. Olive oils high in phenolic compounds modulate oxidative/antioxidative status in men. J Nutr. 2004 Sep;134(9):2314-21. — View Citation

* Note: There are 20 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Stage 1: Maximum plasma concentration (Cmax) 24 hour dosing period; 2 dosing periods each separated by 7 days washout 24 hours
Primary Stage 1: Concentration at the end of the dosing interval (Ct) 24 hour dosing period; 2 dosing periods each separated by 7 days washout 24 hours
Primary Stage 1: Time until Cmax is reached (Tmax) 24 hour dosing period; 2 dosing periods each separated by 7 days washout 24 hours
Primary Stage 1: Area under the curve from administration to last observed concentration at time (AUC (0-t) 24 hour dosing period; 2 dosing periods each separated by 7 days washout 24 hours
Primary Stage 1: AUC extrapolated to infinite time (AUC (0-8) 24 hour dosing period; 2 dosing periods each separated by 7 days washout 24 hours
Primary Stage 1: Percentage of AUC extrapolated (AUC%) 24 hour dosing period; 2 dosing periods each separated by 7 days washout 24 hours
Primary Stage 1: Terminal elimination rate constant (Kel) 24 hour dosing period; 2 dosing periods each separated by 7 days washout 24 hours
Primary Stage 1: Plasma concentration half-life (t ½) 24 hour dosing period; 2 dosing periods each separated by 7 days washout 24 hours
Primary Stage 1: Volume of distribution (Vd/ F) 24 hour dosing period; 2 dosing periods each separated by 7 days washout 24 hours
Primary Stage 1: Clearance (Cl/F) 24 hour dosing period; 2 dosing periods each separated by 7 days washout 24 hours
Primary Stage 1: Peak trough fluctuation over one dosing interval at steady state (PTF) 24 hour dosing period; 2 dosing periods each separated by 7 days washout 24 hours
Primary Stage 1: Cmax dose normalized (Cmax/Dose) 24 hour dosing period; 2 dosing periods each separated by 7 days washout 24 hours
Primary Stage 1: AUC (0-t) dose normalized (AUC (0-t)/Dose) 24 hour dosing period; 2 dosing periods each separated by 7 days washout 24 hours
Primary Stage 1: Urine polyphenols concentration 24 hour dosing period; 2 dosing periods each separated by 7 days washout 24 hours
Primary Stage 1: Urine triterpenes concentration 24 hour dosing period; 2 dosing periods each separated by 7 days washout 24 hours
Primary Stage 2: Plasma polyphenols concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Primary Stage 2: Plasma triterpenes concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Primary Stage 2: Urine polyphenols concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Primary Stage 2: Urine triterpenes concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Primary Stage 2: Malondialdehyde concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Primary Stage 2: Catalase concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Primary Stage 2: Glutathione peroxidase concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Primary Stage 2: Superoxide dismutase concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Primary Stage 2: F2A isoprostane concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Primary Stage 2: 8 isoprostane concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Primary Stage 2: Oxidized low-density lipoprotein concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Primary Stage 2: C-Reactive Protein concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Primary Stage 2: Lipoprotein-associated phospholipase A2 concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Primary Stage 2: Apolipoprotein A1 concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Primary Stage 2: Apolipoprotein B100 concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Primary Stage 2: Tumor necrosis factor alpha concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Primary Stage 2: Interleukin 6 concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Primary Stage 2: Interleukin 1 concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Secondary Stage 1 and 2: Number of participants with treatment-related adverse events 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Secondary Stage 1 and 2: Systolic and diastolic blood pressure Stage 1: 24 hours, Stage 2: 30 days Stage 1: 24 hour dosing period; 2 dosing periods each separated by 7 days washout, Stage 2: 30 days dosing period or 30 days as control group separated by 15 days washout
Secondary Stage 1 and 2: Heart rate Stage 1: 24 hours, Stage 2: 30 days Stage 1: 24 hour dosing period; 2 dosing periods each separated by 7 days washout, Stage 2: 30 days dosing period or 30 days as control group separated by 15 days washout
Secondary Stage 1 and 2: Respiratory rate Stage 1: 24 hours, Stage 2: 30 days Stage 1: 24 hour dosing period; 2 dosing periods each separated by 7 days washout, Stage 2: 30 days dosing period or 30 days as control group separated by 15 days washout
Secondary Stage 2: Body weight 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Secondary Stage 2: High-density lipoprotein cholesterol concentration (HDL-C) 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Secondary Stage 2: Low-density lipoprotein cholesterol concentration (LDL-C) 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Secondary Stage 2: Very low-density lipoprotein cholesterol concentration (VLDL-C) 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Secondary Stage 2: Triglyceride concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Secondary Stage 2: Total cholesterol concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Secondary Stage 2: Sodium concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Secondary Stage 2: Glucose concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Secondary Stage 2: Urea concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Secondary Stage 2: Creatinine concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Secondary Stage 2: Aspartate aminotransferase concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Secondary Stage 2: Alanine aminotransferase concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Secondary Stage 2: Alkaline phosphatase concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
Secondary Stage 2: Total proteins concentration 30 days 30 days dosing period or 30 days as control group separated by 15 days washout
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1